Last reviewed · How we verify

NCT04292353: WP-12

Cerebral Morbidity After Radiation Therapy for Brain Tumors

Status unknown Last updated 5 May 2021
What this trial tests

trial testing Cognitive tests and Patient Reported Outcome in Brain Tumor in 67 participants. Status unknown.

Timeline
1 July 2016
Primary endpoint
30 September 2024
30 September 2024

Quick facts

Lead sponsorUniversity of Aarhus
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment67
Start date1 July 2016
Primary completion30 September 2024
Estimated completion30 September 2024
Sites4 locations across Denmark

Drugs / interventions tested

Conditions studied

Sponsor

University of Aarhus

Who can join

Adults 18 to 100, any sex, with Brain Tumor or Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will assess cognitive function in patients with a primary brain tumour treated with radiation therapy (RT) to generate radio-sensitivity and volume effect parameters for the development of cognitive dysfunction. All types of brain tumours apart from glioblastoma will be included.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Brain Tumor

Currently open trials in the same condition.

Other University of Aarhus trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04292353.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing